Mechanisms and preclinical efficacy of silibinin in preventing skin cancer

European Journal of Cancer

Volumn 41, Issue 13, 2005, Pages 1969-1979

  Singh, Rana P ^a   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; DNA repair; Mitogenic and survival signaling; p53; Photocarcinogenesis; Silibinin

Indexed keywords

CARCINOGEN; CYTOTOXIC AGENT; REACTIVE OXYGEN METABOLITE; SILIBININ; TUMOR PROMOTER;

CELL CULTURE; CELL CYCLE; CELL SURVIVAL; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INFLAMMATION; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SILYBUM MARIANUM; SKIN CANCER; SKIN CARCINOGENESIS; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION;

EID: 27644439523     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.03.033     Document Type: Article

References (94)

1. Singh RP, Agarwal R. SENCAR mouse skin tumourigenesis model. In Teicher BA, ed. Tumour models in cancer research. Totowa (NJ), Humana Press, 2001. pp. 359-380.
2. Zoumpourlis V, Solakidi S, Papathoma A, et al. Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. Carcinogenesis 2003, 24, 1159-1165.
3. Harris RB, Alberts DS. Strategies for skin cancer prevention. Int J Dermatol 2004, 43, 243-251.
4. McKenzie R, Connor B, Bodeker G. Increased summertime UV radiation in New Zealand in response to ozone loss. Science 1999, 285, 1709-1711.
5. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer 2004, 4, 23-35.
6. Gloster Jr HM, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996, 22, 217-226.
7. Matsui MS, DeLeo VA. Photocarcinogenesis by ultraviolet A and B. In Mukhtar H, ed. Skin cancer: mechanisms and human relevance. Boca Raton (FL), CRC Press, 1995. pp. 21-30.
8. Kanjilal S, Ananthaswamy HN. In Weber R, Miller M, Goepfert H, eds. Basal and squamous cell skin cancers of the head and neck. Baltimore, Williams and Wilkins, 1996. pp. 25-26.
9. Pourzand C, Tyrrell RM. Apoptosis, the role of oxidative stress and the example of solar UV radiation. Photochem Photobiol 1999, 70, 380-390.
10. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994, 372, 773-776.
11. Gilchrest BA. A review of skin ageing and its medical therapy. Br J Dermatol 1996, 135, 867-875.
12. Cruz JR, Leverkus PDM, Dougherty I, et al. Thymidine dinucleotides inhibit contact hypersensitivity and activate the gene for tumour necrosis factor alphal. J Invest Dermatol 2000, 114, 253-258.
13. Kulms D, Schwarz T. Molecular mechanisms of UV-induced apoptosis. Photodermatol Photoimmunol Photomed 2000, 16, 195-201.
14. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 2004, 195, 298-308.
15. Chin L. The genetics of melanoma: lessons from mouse and man. Nat Rev Cancer 2003, 3, 559-570.
16. Wolf P, Donawho CK, Kripke ML. Effect of sunscreens on UV radiation-induced enhancement of melanoma growth in mice. J Nat Cancer Inst 1994, 86, 99-105.
17. Pinnell SR. Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol 2003, 48, 1-19.
18. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA 1995, 92, 5258-5265.
19. Potter JD. Cancer prevention: epidemiology and experiment. Cancer Lett 1997, 114, 7-9.
20. Sporn MB, Suh N. Chemoprevention: an essential approach in controlling cancer. Nat Rev Cancer 2002, 2, 537-543.
21. Bickers DR, Athar M. Novel approaches to chemoprevention of skin cancer. J Dermatol 2000, 27, 691-695.
22. Bode AM, Dong Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 2000, 1, 181-188.
23. Hong JT, Kim EJ, Ahn KS, et al. Inhibitory effect of glycolic acid on ultraviolet-induced skin tumourigenesis in SKH-1 hairless mice and its mechanism of action. Mol Carcinog 2001, 31, 152-160.
24. Lu YP, Lou YR, Lin Y, et al. Inhibitory effects of orally administered green tea, black tea, and caffeine on skin carcinogenesis in mice previously treated with ultraviolet B light (highrisk mice): relationship to decreased tissue fat. Cancer Res 2001, 61, 5002-5009.
25. Conney AH. Tailoring cancer chemoprevention regimens to the individual. J Cell Biochem 2004, 91, 277-286.
26. Huang MT, Xie JG, Wang ZY, et al. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res 1997, 57, 2623-2629.
27. Katiyar SK, Korman NJ, Mukhtar H, et al. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997, 89, 56-66.
28. Lu YP, Lou YR, Xie JG, et al. Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumours in mice. Proc Natl Acad Sci USA 2002, 99, 12455-12460.
29. Mallikarjuna G, Dhanalakshmi S, Singh RP, et al. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signalling. Cancer Res 2004, 64, 6349-6356.
30. Zhao J, Sharma Y, Agarwal R. A Flavonoid antioxidant, silymarin, affords significant inhibition against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interlukin-1 α expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumour. Mol Carcinog 1999, 26, 321-333.
31. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, et al. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumour promotion in the SENCAR mouse skin tumourigenesis model. Cancer Res 1999, 59, 622-632.
32. Singh RP, Tyagi AK, Zhao J, et al. Silymarin inhibits growth and causes regression of established skin tumours in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis 2002, 23, 499-510.
33. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 2002, 4, 655-663.
34. Blumenthal M. Herbs sales down 3% in mass market retail stores: sales in natural food stores still growing, but at lower rate. HerbalGram 2000, 49, 68.
35. Wagner H, Diesel P, Seitz M. Chemistry and analysis of silymarin from Silybum marianum (L) Gaertn. Arzneimittelforsch 1974, 24, 466-471.
36. Wellington K, Jarwis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001, 15, 465-489.
37. Trost W, Halbach G. Anti-phalloidine and anti-alpha-amanitine action of silybin in comparison with compounds similar to structural parts of silybin. Experientia 1978, 34, 1051-1052.
38. Trinchet JC, Coste T, Levy VG, et al. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol 1989, 13, 120-124.
39. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998, 28, 615-621.
40. Vogel G, Trost W, Braatz R. Studies on the pharmacodynamics, including site and mode of action, of silymarin: the antihepatotoxic principle from Silybum marianum (L) Gaertn. Arzneimittelforsch 1975, 25, 82-89.
41. Singh RP, Dhanalakshmi S, Tyagi AK, et al. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002, 62, 3063-3069.
42. Agarwal C, Singh RP, Dhanalakshmi S, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003, 22, 8271-8282.
43. Bhatia N, Zhao J, Wolf DM, et al. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 1999, 147, 77-84.
44. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 2004, 4, 1-11.
45. Tyagi AK, Agarwal C, Singh RP, et al. Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papillomas RT4 cells. Biochem Biophys Res Commun 2003, 312, 1178-1184.
46. Sharma G, Singh RP, Chan DC, et al. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res 2003, 23, 2649-2655.
47. Kohno H, Tanaka T, Kawabata K, et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002, 101, 461-468.
48. Singh RP, Mallikarjuna GU, Sharma G, et al. Oral silibinin inhibits lung tumour growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 2004, 10, 8641-8647.
49. Zi X, Mukhtar H, Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumour promoter TNFα. Biochem Biophys Res Commun 1997, 239, 334-339.
50. Zhao J, Lahiri-Chatterjee M, Sharma Y, et al. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumour promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis 2000, 21, 811-816.
51. Tornaletti S, Pfeifer GP. UV damage and repair mechanisms in mammalian cells. Bioessays 1996, 18, 221-228.
52. Lu YP, Lou YR, Yen P, et al. Time course for early adaptive responses to ultraviolet B light in the epidermis of SKH-1 mice. Cancer Res 1999, 59, 4591-4602.
53. Dhanalakshmi S, Mallikarjuna GU, Singh RP, et al. Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis 2004, 25, 1459-1465.
54. Mallikarjuna G, Dhanalakshmi S, Singh RP, et al. Dietary feeding of silibinin prevents early biomarkers of ultraviolet B radiation-induced Carcinogenesis in SKH-1 hairless mouse epidermis. Cancer Epidemiol Biomark Prev 2005, 14, 1344-1349.
55. Mukhtar H, Agarwal R. Skin cancer chemoprevention. J Invest Dermatol Sym Proc 1996, 1, 209-214.
56. Fischer SM, Slaga TJ. Arachidonic acid metabolism and tumour promotion. Boston, Martinus Nijhoff Publishing, 1985., pp. 1-263.
57. DiGiovanni J. Multistage Carcinogenesis in mouse skin. Pharmacol Ther 1992, 54, 63-128.
58. Li G, Ho VC. p53-dependent DNA repair and apoptosis respond differently to high- and low-dose ultraviolet radiation. Br J Dermatol 1998, 139, 3-10.
59. Ouhtit A, Muller HK, Davis DW, et al. Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am J Pathol 2000, 156, 201-207.
60. Ramzi ST, Maruno M, Khaskhely NM, et al. An assessment of the malignant potential of actinic keratoses and Bowen's disease: p53 and PCNA expression pattern correlate with the number of desmosomes. J Dermatol 2002, 29, 562-572.
61. Mass P, Hoffmann K, Gambichler T, et al. Premature keratinocyte death and expression of marker proteins of apoptosis in human skin after UVB exposure. Arch Dermatol Res 2003, 295, 71-79.
62. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995, 11, 199-210.
63. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408, 307-310.
64. Bode AM, Dong Z. Post-translational modification of p53 in tumourigenesis. Nat Rev Cancer 2004, 4, 793-805.
65. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci USA 1996, 93, 4827-4832.
66. Mullauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 2001, 488, 211-231.
67. Fuchs SY, Adler V, Buschmann T, et al. Mdm2 association with p53 targets its ubiquitination. Oncogene 1998, 17, 2543-2547.
68. Olivier M, Hussain SP, Caron de Fromentel C, et al. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004, 157, 247-270.
69. Dhanalakshmi S, Agarwal C, Singh RP, et al. Silibinin upregulates DNA-PK-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells. J Biol Chem 2005, 280, 20375-20383.
70. Dhanalakshmi S, Mallikarjuna GU, Singh RP, et al. Dual-efficacy of silibinin in protecting or enhancing ultraviolet B radiation-caused apoptosis in human immortalized keratinocyte HaCaT cells. Carcinogenesis 2004, 25, 99-106.
71. Chen X, Ko LJ, Jayaraman L, et al. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumour cells. Genes Dev 1996, 10, 2438-2451.
72. Seger R, Krebs EG. The MAPK signalling cascade. FASEB J 1995, 9, 726-735.
73. Chen W, Bowden GT. Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes. Oncogene 1999, 18, 7469-7476.
74. Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003, 2003, 1-15.
75. Boldt S, Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002, 23, 1831-1838.
76. Mallikarjuna G, Dhanalakshmi S, Mohan S, et al. Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signalling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis, 2005 April 14 [Epub ahead of print].
77. Cheng M, Sexl V, Sherr CJ, et al. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 1998, 95, 1091-1096.
78. Ponten F, Berne B, Ren ZP, et al. Ultraviolet light induces expression of p53 and p21 in human skin: effect of sunscreen and constitutive p21 expression in skin appendages. J Invest Dermatol 1995, 105, 402-406.
79. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004, 4, 592-603.
80. Cotton J, Spandau DF. Ultraviolet B-radiation dose influences the induction of apoptosis, and p53 in human keratinocytes. Radiat Res 1997, 147, 148-155.
81. Testa JR, Bellacosa A. AKT plays a central role in tumourigenesis. Proc Natl Acad Sci USA 2001, 98, 10983-10985.
82. Gottlieb TM, Leal JF, Seger R, et al. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002, 21, 1299-1303.
83. Bachelder RE, Ribick MJ, Marchetti A, et al. p53 inhibits alpha 6 beta 4 integrin survival signalling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 1999, 147, 1063-1072.
84. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001, 7, 542-547.
85. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22, 8581-8589.
86. Alien SM, Florell SR, Hanks AN, et al. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumour progression. Cancer Res 2003, 63, 567-572.
87. Morgan DO. Principles of CDK regulation. Nature 1995, 374, 131-134.
88. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13, 1501-1512.
89. Ducoux M, Urbach S, Baldacci G, et al. Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA replication through a conserved p21(Cip1)-like PCNA-binding motif present in the third subunit of human DNA polymerase delta. J Biol Chem 2001, 276, 49258-49266.
90. Fotedar R, Bendjennat M, Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle 2004, 3, 134-137.
91. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994, 8, 9-22.
92. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001, 1, 22-33.
93. Smith ML, Fornace Jr AJ. p53-mediated protective responses to UV irradiation. Proc Natl Acad Sci USA 1997, 94, 12255-12257.
94. Kunkel TA, Bebenek K. DNA replication fidelity. Annu Rev Biochem 2000, 69, 497-529.